If the choice is made to anticoagulate patients with symptomatic isolated distal deep vein thrombosis (DVT), outcomes will be improved with 12 versus 6 weeks of treatment, the randomized, ...

Please provide your email address to receive an email when new articles are posted on . Adults with isolated distal deep vein thrombosis experience fewer short- and long-term adverse outcomes compared ...

Please provide your email address to receive an email when new articles are posted on . Longer vs. shorter-duration anticoagulation reduces thrombotic event risk for patients with cancer and isolated ...

Effect of a Community Health Worker–Led Intervention Among Low-Income and Minoritized Patients With Cancer: A Randomized Clinical Trial More than 90% of patients in each group were treated with ...

Giving the anti-clotting drug rivaroxaban to patients for 12 weeks instead of the usual six after a blood clot in the lower leg reduces the risk of further clots developing up to two years after ...

Deep vein thrombosis (DVT) occurs when a blood clot forms in a large (deep) vein. Proximal DVTs occur in deep veins above the knee and isolated, distal DVTs can occur when smaller blood clots form in ...

The mainstay of treatment for DVT is anticoagulation therapy. However, optimal anticoagulation strategies for cancer patients with isolated distal DVT are not currently established. ONCO DVT was the ...

Giving the direct oral anticoagulant (DOAC) edoxaban for 12 months rather than 3 months is better for preventing thrombotic events in patients with active cancer and isolated deep-vein thrombosis (DVT ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window AMSTERDAM -- A ...

Patients with active cancer and newly diagnosed isolated distal deep vein thrombosis (DVT) who received 12 months of edoxaban (Savaysa) had fewer thrombotic events at 1 year than those who received 3 ...

But doctors are still not sure whether all patients with distal DVT should receive anticoagulation, and for how long. To address this uncertainty, researchers set out to compare two different ...